Physician profile
Mark A Wrona
NPI 1003909565
$1,571.52
in general payments reported to CMS, 2019-2025
29 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 96% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2021: $68.16 · 2022: $124 · 2024: $27.50 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $204.95 | 2021-2025 | Zynyz, Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals Lp | $183.55 | 2025 | Tagrisso, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $171.93 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $103.55 | 2025 | Erleada, Rybrevant |
| Genzyme Corporation | $88.97 | 2025 | |
| Abbvie INC. | $72.67 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $67.84 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.19 | 2019-2025 | Opdivo |
| Collegium Pharmaceutical, INC. | $57.92 | 2019 | |
| Stemline Therapeutics INC. | $54.55 | 2025 | Orserdu, Elzonris |
| Merck Sharp & Dohme LLC | $47.78 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Sobi, INC | $42.96 | 2025 | |
| Novocure INC. | $40.55 | 2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $35.01 | 2021-2025 | |
| Caris Mpi, INC. | $32.80 | 2025 | Mi Cancer Seek |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $31.13 | 2025 | Zenpep |
| Amgen INC. | $24.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.74 | 2019 | |
| Exelixis INC. | $23.48 | 2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $23.47 | 2021 | |
| Glaxosmithkline, LLC. | $22.99 | 2025 | Ojjaara |
| Puma Biotechnology, INC. | $22.18 | 2025 | |
| Pharmacosmos Therapeutics INC. | $22.08 | 2025 | Monoferric |
| Alnylam Pharmaceuticals INC. | $20.14 | 2025 | Givlaari |
| Adc Therapeutics America, INC. | $20.04 | 2025 | |
| Eisai INC. | $18.04 | 2025 | |
| Gilead Sciences, INC. | $16.89 | 2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $16.02 | 2019 | |
| Pfizer INC. | $15.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wrona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.